Myasthenia Gravis

       What is Myasthenia Gravis? Myasthenia gravis is an autoimmune disorder caused by the presence of autoantibodies specific to human acetylcholine receptor (ACHR), which is concentrated in the synapses of the neuromuscular junction post. Myasthenia Gravis (MG) is a chronic, autoimmune causes muscle weakness and muscle fatigue slowly but progressively. If the patient is at rest, it is not long before muscle power will be restored. The disease is caused by the disruption of synaptic transmission at the neuromuscular junction.

Symptoms of muscle weakness, muscle fatigue that is not fair, and increased muscle strength after resting a characterization of myasthenia gravis. Symptoms tend to be worse at the end of the day or after the event, and after the use of muscles repeatedly to perform a certain action, such as chewing and swallowing, it is likely the movement is much more difficult when had finished eating than early eating.

History of Myasthenia Gravis
       The most comprehensive research and rational about the cases of myasthenia gravis (MG) was first performed by Erb (1878) along with Goldflam (1893) which indicate the presence of bulbar palsy in the absence of anatomical lesions. For several years this disorder called Erb-Goldflam syndrome. The first to use the name of myasthenia gravis (MG) is Jolly (1895), in which case the term Jolly adds pseudoparalisis that leads to the least structural changes in the patient's body at autopsy. Jolly also was the first to demonstrate that myasthenic weakness could be caused by repetitive stimulation on motorneuron and "fatigue" the muscle still responds galvanic stimulation. What's interesting about the study Jolly was already put forward suggestions in the use of physostigmine as a form of treatment, but it is only really consider when Remen (1932) and Walker (1934) demonstrated the therapeutic ability of the drug.

       The relationship between myasthenia gravis (MG) with the thymus gland was first noted by lacquer and Wegert in 1901, and in 1949 Castleman and Noris clearly describe pathological changes in the thymus gland.

        In 1905 Buzard published clinical pathology analysis of myasthenia gravis (MG) in detail. Which reported an abnormal thymus gland and lymphocyte infiltration in muscles (lymphorrhages). In the study mentioned that ototoksik agent from limforargi and thymic lesions causing muscle weakness. Buzard also said the relationship between myasthenia gravis (MG) with a grave disease and Addison's disease, which has now been categorized as an autoimmune disease. In the end that is really to categorize myasthenia gravis (MG) is an autoimmune disease research conducted by Patrick, Lindstrom, Fambrough, Lenon and Engel in 1973.

         Myasthenia gravis (MG) affects all races and can develop at any age from infancy to old age. Myasthenia Gravis (MG) actually includes a rare disease, an estimated annual incidence of 2 per 1,000,000. In young patients more often experience are women, while older patients, more than 50 years, more often male. Comparison of the incidence of women to men is 6:4, but as population growth, the ratio is now almost the same ratio. People who inherit a tendency to develop autoimmune disease are at increased risk of myasthenia gravis (MG), so patients with myasthenia gravis (MG) may have other autoimmune diseases, such as diabetes or thyroid disease, or have relatives with autoimmune diseases. Myasthenia gravis is the most common type of neuromuscular junction disorders nonherediter (62%), most types of disorder is a disorder of the eyes (89%).

RELATED ARTICLES


 
•    Pathophysiology of Myasthenia Gravis
•    Clinical Manifestations of Myasthenia Gravis
•    Diagnosis of Myasthenia Gravis
•    Medical Treatment and Therapy of Myasthenia Gravis

MEDICAL BOOKS ABOUT MYASTHENIA GRAVIS

Resources

1. Picture: http://www.myasthenia.org.au/html/symptoms.htm